LONDON--(BUSINESS WIRE)--RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that three-month data from an in vivo study of its StronBone™ bioactive glass with Strontium demonstrated that it can generate bone quality in and around defects that appears by analytical tests to be significantly superior to a standard bone void filler in the control defect.
